Associate Director
Ascidian Therapeutics
Associate Director
Ascidian Therapeutics
RNA exon editing for gene therapies
Engagement: Contract, approximately 20 hours/week, with potential to transition to full-time
About Ascidian:
Ascidian is redefining the treatment of disease by rewriting RNA.
We were founded on a bold vision: to transform the treatment of genetic diseases by editing and replacing human exons at the RNA level. Our inspiration comes from ascidians, remarkable marine creatures that are evolutionary ancestors of vertebrates. As they develop from larvae into adults, ascidians re-engineer their transcriptome through RNA processing mechanisms, including trans-splicing and alternative splicing.
Today, Ascidian is a clinical-stage privately-owned biotech company pioneering a new approach to genetic medicine through RNA exon editing. By precisely editing RNA rather than DNA, our therapies are designed to enable the production of full-length, functional proteins at the right levels, in the right cells, and at the right time.
With partnered and wholly owned programs spanning retinal, renal, neurological, neuromuscular, and other genetically defined diseases, Ascidian is advancing a differentiated therapeutic platform with the potential to deliver lasting benefits from a single dose of an RNA exon editor. Our approach opens new possibilities for patients and families seeking transformative treatments.
About the Role
As we advance our pipeline towards the clinic, we’re looking for a highly motivated and experienced Program Management expert to join our dynamic team. This role begins as a contract engagement of approximately 20 hours per week, with the potential to transition to a full-time position.
As a Program Manager at Ascidian Therapeutics, the individual will be instrumental in working closely with the core program team, ensuring milestones are delivered on time, within scope, and on budget. Working alongside our program lead and functional experts, you’ll build and own the integrated plans that connect Research, Clinical, Regulatory, CMC, and nonclinical teams moving IND-enabling work into the clinic. Program strategy, research and clinical decisions sit with the program lead. Your role is to frame the options, balance quality, speed, and cost, and guide the team to clear decisions, then make sure those decisions are carried through. This is a hands-on role for someone who digs into the details, raises risks early, and builds trusted relationships across the company to keep work moving.
This role requires strong communication skills, meticulous attention to detail, and the ability to navigate complex scientific and operational challenges within a fast-paced, early-stage biotech environment. Another key success factor is the ability to closely partner with cross-functional teams across both internal functions and external partners, translating strategic goals into actionable plans and tracking progress toward key milestones.
Key Responsibilities
Qualifications
Why Join Ascidian?
At Ascidian Therapeutics, you’ll be part of a team that is redefining the future of medicine. We offer:
If you are a driven and passionate Program Management professional looking to make a significant impact in a rapidly evolving field, we encourage you to apply!
Ascidian Therapeutics is an equal opportunity employer and values diversity. All employment is decided on the basis of qualifications, merit, and business need.
RNA exon editing for gene therapies
Ascidian Therapeutics focuses on RNA exon editing to treat diseases. It develops technologies that edit RNA transcripts after they are made from DNA, enabling precise changes while keeping natural gene expression patterns. This approach aims to produce full-length, functional proteins and offer durable therapeutic effects without direct DNA editing or gene replacement. The company monetizes by licensing its RNA exon editing technology to healthcare providers and research institutions and may also participate in development and sale of therapies based on its platform. Compared with competitors, it emphasizes transcriptome re-engineering in human cells to achieve steady gene expression without altering the genome, reducing certain genetic risks while maintaining normal regulatory control. The overall goal is to translate RNA exon editing into accessible therapies for patients by partnering for licensing and therapy development.
Explore more opportunities at Ascidian Therapeutics